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Disentangling psychopathology, substance
use and dependence: a factor analysis
Jaime Delgadillo1,2* , Jan R. Böhnke2, Elizabeth Hughes3 and Simon Gilbody2
Abstract
Background: The notion that substance use can induce symptoms of depression and anxiety is influential in
clinical practice, however questions remain about the empirical support for this hypothesis.
Methods: We analysed mental health and substance dependence screening records for 280 outpatients in
addictions treatment. Item-level data for depression (PHQ-9), anxiety (GAD-7), severity of dependence (SDS) and
self-reported weekly substance use were studied using factor analysis and correlations. Symptom-level associations
between substance use and psychological distress symptoms were examined after controlling for underlying levels
of psychopathology.
Results: We obtained a two-factor solution accounting for approximately 48 % of total variance. Depression and
anxiety symptoms loaded onto a single psychopathology factor. Severity of dependence (SDS) and substance use
measures loaded onto a distinct but correlated factor. After controlling for latent levels of psychopathology, the
only remaining symptom-level associations were impaired concentration linked to cannabis use and irritability
linked to alcohol use. Dependence (SDS) was prominently associated with depressive rumination, and negatively
correlated with residual anxiety symptoms related to substance use (e.g., craving).
Conclusions: Overall, this analysis supports a psychological understanding of comorbidity; with dependence,
craving, negative reinforcement and rumination as key variables.
Keywords: Depression, Anxiety, Alcohol, Drugs, Addiction
Background
Substance use disorders and common mental disorders
(CMD) such as depression and anxiety often co-exist.
This finding is consistent across epidemiological surveys
conducted in the general population [1–4] and in clinical
samples [5–7]. Many have interpreted this common
overlap in disorders as evidence that substance use can
induce or mimic depressive and anxiety symptoms. The
notion of substance induced disorders has a firmly
anchored place in diagnostic manuals [8, 9], structured
assessment interviews [10–12] and clinical practice
guidelines in the addictions field [13–15]. An illustrative
example of the reification of this assumption is offered
by Raimo and Schuckit who assert that –when assessing
alcohol users– “unless independent major depressive
syndromes are clearly established, it is assumed that the
only depressive episodes that have been experienced
were likely to be substance induced” [16], p. 935.
Although the substance induced hypothesis continues
to influence current clinical practice, there is some
contention about its empirical foundations. More recent
epidemiological surveys [17, 18] found that substance
induced depression and anxiety disorders are less
common than expected (≤10 % of cases in clinical sam-
ples, and <1 % in the general population). Several clinical
reports have noted that substance users’ psychological
distress symptoms remitted after a brief period of ob-
servation, typically within less than a month [19–21].
Such reports are taken to indicate that a reduction of
psychoactive substance use may account for improved
psychological state, but they do not account for or rule
out the possible influence of other ‘third’ or potentially
mediating variables. For example, large cross-sectional
and longitudinal surveys have demonstrated that this
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combination of disorders appears to be mostly promin-
ent in people who meet criteria for alcohol or sub-
stance dependence, rather than in those with less
chronic or episodic substance use [22, 23]. This raises
questions about whether there is indeed a causal rela-
tionship between levels of substance use and symptoms
of CMD. An alternative possibility is that substance de-
pendence as a psychological and behavioural syndrome
may be associated with CMD, irrespective of the level
of consumption. Severity of dependence is known to
correlate with level of substance use and psychopath-
ology; however symptoms of dependence can neverthe-
less be present in abstainers [24].
Furthermore, most studies in this area examine associ-
ations at the level of syndromes or disorders, which
could possibly mask specific symptom-level relationships
and could also introduce artificial relationships because
of double counting of symptoms [25]. For instance, in a
recent study, severity of dependence has been found to
correlate with several symptoms of depression and anx-
iety, whereas only few CMD symptoms were correlated
with level of substance use and abstainers were just as
likely to have a CMD diagnosis compared to users [26].
Symptom-level associations such as these have rarely
been examined, and until such studies proliferate the de-
bate about causal links will probably continue unabated.
In the present paper, we examine the relationships be-
tween substance use, severity of dependence and CMD
at the level of symptoms and latent dimensions of psy-
chopathology. The main aims of this study were to de-
termine the factor structure of a battery of measures
covering the above domains in a clinical sample, and to
describe and interpret the patterns of symptom-level
associations.
Methods
Design and context
This paper presents factor analyses and correlations
based on pooled data from two prior studies that applied
a mental health screening strategy in addiction services
[27, 28]. Both studies recruited patients accessing
community based alcohol, drug and rehabilitation
teams in a large city in the north of England. These
were multi-disciplinary teams offering access to med-
ical (e.g., opiate substitute treatment) and psycho-
social input to minimise harms associated with
substance use and to support access to housing, social
care, training, peer mentorship and employment op-
portunities. Interventions offered by these services
were consistent with national guidelines for the man-
agement of substance use disorders [29, 30].
Both studies purposefully aimed to screen patients at
various stages of their contact with addiction services
(range of months in treatment = 0–70), which would
ensure results were less likely to be confounded by the
acute distress typically observed in new patients. Both
studies enlisted the support of drug and alcohol workers
to screen participants, and applied methods to minimise
selection bias (database searches, use of appointment
and reminder systems to prompt clinicians to contact
potential participants). Both studies applied the same
patient reported outcome measures (PROMs) to identify
patients with CMD. Further details of the primary
studies and recruitment methods can be found in the
source publications.
Informed consent was provided by all participants
across both studies to use their anonymous data as part
of research, and ethical approval was provided by the
University of York [reference: RGC/03.07.09] and the
English National Health Service Research Ethics Com-
mittee [REC reference: 12/YH/0096].
Psychometric measures and screening strategy
Four PROMs were applied to screen for substance use,
dependence and symptoms of common mental health
problems.
Addiction related measures
The Treatment Outcomes Profile (TOP) is a twenty-
item measure covering four domains: substance use,
injecting risk behaviour, crime and health & social
functioning [31]. The measure is based on the time-
line follow-back method [32]; which prompts respon-
dents to recall the average quantity and frequency of
substances used during the last 4 weeks. The TOP has
been reported to have adequate sensitivity (0.57–0.89) and
specificity (0.85–0.92) compared to independent drug
toxicology tests.
The Severity of Dependence Scale (SDS) is a measure of
psychological dependence, capturing aspects of compul-
sive substance use, concern over use and degree of control
over use [33]. This five-item questionnaire yields a total
score between 0 and 15, where scores above 10 are indica-
tive of severe dependence. The SDS has been extensively
validated as a reliable screening tool for dependence on a
variety of substances including alcohol, heroin, crack,
cannabis and other illicit and prescription drugs [34–38].
Patients in the source studies were asked to complete the
SDS measure only for their primary substance of concern
(most frequently used and/or the index substance for
which they sought treatment in the case of abstainers).
The internal reliability (Cronbach’s alpha) estimate for the
SDS in the study sample was α = .85.
Common mental disorder (CMD) related measures
The PHQ-9 is a nine-item questionnaire based on
diagnostic criteria for major depression, which renders a
severity score between 0 and 27 [39]. The PHQ-9 has
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been validated as a reliable case-finding tool for clinically
significant depression symptoms in substance users
based on a cut-off score ≥12, with 81 % sensitivity and
75 % specificity [27]. Cronbach’s alpha for PHQ-9 in this
study sample was α = .83.
The GAD-7 questionnaire [40] was used to assess se-
verity of anxiety symptoms, with scores ranging between
0 and 21, where a score ≥9 indicates the likely presence
of an anxiety disorder with 80 % sensitivity and 86 %
specificity [41]. Cronbach’s alpha for GAD-7 in this
study sample was α = .88.
The TOP questionnaire cited above also contains a
single item psychological health scale (TOP-4a), which
asks respondents to rate their psychological wellbeing
on a scale of 0 (poor) to 20 (good). A cut-off score ≤12
on the TOP-4a has been found to have adequate sensi-
tivity (83 %) and specificity (71 %) to detect a probable
diagnosis of a CMD [42].
Sample characteristics
A total of 280 screening records were included in this
study. Most respondents were white British (80.3 %)
males (74.5 %), with a mean age of 36.74 (SD = 7.18;
range = 23 – 60). The majority (97.1 %) were prescribed
opiate substitute medication, but less than half (40.7 %)
were prescribed antidepressants. The most commonly
used substances in this sample were alcohol (47.1 %
of users), heroin (42.9 %), cannabis (23.9 %), crack
(23.2 %), benzodiazepines (6.4 %), cocaine (3.6 %), and
amphetamines (2.1 %). Approximately 47.5 % were poly-
substance users, 17.5 % reported intravenous use, and
17.5 % reported being currently abstinent for at least a
month. Weekly substance use estimates are presented in
Table 1 for the four most commonly used substances
(alcohol, heroin, cannabis and crack). Mean scores for
PROMs were SDS = 7.08 (SD = 4.69); PHQ-9 = 13.58
(SD = 6.14); GAD-7 = 10.28 (SD = 5.58); TOP-4a = 9.95
(SD = 4.29). According to mental health measures,
61.8 % had clinically significant depression (PHQ-9)
symptoms, 59.2 % had clinically significant anxiety
(GAD-7) symptoms, and 73.5 % were likely to meet cri-
teria for a CMD (TOP-4a).
Statistical analyses
Consistent with the aims of this study, statistical analyses
were performed in 3 stages focusing on (1) describing
the sample, (2) undertaking factor analyses, and (3) ex-
ploring associations between screening domains. The
following analyses were performed with IBM SPSS 22
and FACTOR 9.3.1.
Descriptive statistics are reported for demographic
characteristics, and mean levels of substance use, sever-
ity of dependence, depression and anxiety symptoms. To
enhance the precision of substance use information
gathered by the TOP questionnaire, we calculated quan-
tity x frequency (QF) measures by multiplying the aver-
age amount of use in a typical day by the number of
days used in the last week. This method is likely to re-
duce recall bias and has been used in prior correlational
studies [43]. Given the sample size limits, QF measures
were only derived for the 4 most commonly used sub-
stances: alcohol, heroin, crack, cannabis.
Two datasets including all items (N = 26) across
PHQ-9, GAD-7, SDS, TOP-4a and QF measures were
used for factor analyses. Dataset A included 232 (82.9 %)
cases with complete data on all items. Dataset B included
all cases (N = 280), where missing items were imputed
using an expectation-maximization procedure [44].
Conventional analyses were used to empirically evalu-
ate the adequacy of the dataset for factor analysis; these
included the Kaiser-Meyer-Olkin (KMO) test and
Bartlett’s test of sphericity. Since we analysed ordinal
questionnaire responses, polychoric correlations were
used to determine the degree of relationship between
the individual items. In contrast to Pearson correlations,
polychoric correlations assume a monotone relationship
between two variables and the response categories are
not assumed to be equidistant across items [45]. Since
the QF data were highly skewed and not of the same
magnitude across the four different substances, we
transformed them into 5 ordinal variables. The new vari-
ables differentiate between zero (abstainers) versus four
increasing levels of consumption (4 quartile levels of
substance use displayed in Table 1). This transformation
is clinically meaningful, the responses are scaled on a
similar metric to each other, and therefore it enabled us
Table 1 Self-reported substance use variables derived from Treatment Outcomes Profile (TOP)
QF measures Distribution of cases across quintile levels of substance use
Substances Mean SD Range Non-user Light Moderate Frequent Heavy
Alcohol (u) 40.43 53.72 1 – 252 136 32 19 21 24
Heroin (g) 0.91 1.51 0.01 – 10.50 148 35 10 22 17
Cannabis (j) 16.65 16.25 1 – 70 188 11 13 13 7
Crack (g) 0.47 0.68 0.02 – 3.50 191 13 9 10 9
Notes: QF quantity x frequency per week; alcohol measured in units (u); heroin and crack measured in grams (g); cannabis measured in joints (j)
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to analyse these variables together with the items of the
other clinical measures [46].
Our a priori assumptions were that we would find
multiple correlated factors: SDS, a single factor for CMD
symptoms, and 3 factors for QF measures (one for alco-
hol, one for cannabis, and one for heroin and crack
given this common polysubstance use pattern). Based on
this rationale, we performed factor analysis based on un-
weighted least squares, with promin rotation [47]. Next,
we applied Parallel Analysis (PA) [48] and the Hull
method [49] to empirically determine how many factors
optimally explained the variability in the data. While
parallel analysis determines the number of factors that
extract more variability than expected in a structurally
similar set of random data, the Hull Method determines
a solution balancing complexity (degrees of freedom of a
solution) and fit to the data (comparative fit index). This
analysis strategy was initially performed in dataset A,
and replicated in dataset B as a sensitivity analysis.
Finally, we examined item-level correlations between
the domains of substance use and CMD symptoms in
dataset A. These were carried out as partial correlations
controlling for the CMD latent dimension scores derived
from the factor analysis. The rationale for this was to in-
vestigate whether any associations between substance
use and CMD symptoms remain after controlling for
psychopathology. In a second step, these partial correla-
tions additionally controlled for the potential influence
of 'recent quitters' who abstained during 4 weeks and
may be displaying atypical levels of distress [50]. In-
stances with discrepant results between steps 1 and 2 of
analysis prompted us to investigate possible non-linear
associations graphically (using error bars) and statisti-
cally (using polynomial analysis of variance equations).
Results
Factor analysis
Assumption testing
The suitability of applying factor analysis with the set of
26 variables in dataset A was confirmed by Bartlett’s test
of sphericity, which was non-significant (approximate
x2 = 2524.8, df = 325, p < .001). In addition, the overall
KMO measure of sampling adequacy was 0.90, indi-
cating excellent factorability.
Factor structure
In contrast to our expectations, both selection criteria
suggested a two factor solution: Two inter-correlated
(r = .45) latent factors accounted for 47.5 % of variance in
the dataset (35.1 % and 12.4 %, respectively). After promin
rotation, factor 1 included item TOP-4a and all items
from PHQ-9 and GAD-7 (loadings = .50 − .93), thus
representing a latent CMD factor. TOP-4a was negatively
correlated (−.50) with factor 1, since a higher score on this
measure indicates better psychological wellbeing. Factor 2
included all SDS items (loadings = .61 − .90), plus QF
measures for heroin (.53) and crack use (.36), representing
a substance use and dependence (SUD) dimension. QF
measures for alcohol (factor 1 loading = .02, factor 2 = .16)
and cannabis (factor 1 loading = −.11, factor 2 = .17)
were excluded from the final rotated solution, given
their weak correlations which were smaller than the
conventional cut-off of .30.
Repeating these series of analyses in sample B led
to similar results. A two factor solution with the same
item loading structure explained 48.2 % of variance
(factor 1 = 35.5 %, factor 2 = 12.7 %) and the inter-
factor correlation was .43. Therefore, missing data
items were unlikely to influence the results of the
analysis. The final rotated solutions attained in both
samples are displayed in Table 2.
Partial correlations controlling for level of (latent) CMD
psychopathology
Figure 1 displays network plots of item-level partial cor-
relations from the two steps of analysis; where solid and
dashed lines represent positive and negative correlations
respectively. We observed small residual correlations be-
tween PHQ-9 and GAD-7 items after partialling out the
shared CMD factor which explained a large proportion
of variance in both measures. However, contrary to our
expectations, we noted several negative partial correla-
tions between these measures in both steps of analysis
(r = −.13 to–.28).
All SDS items were significantly correlated with
PHQ-9 item 6 (depressive rumination; r = −.19 − .31) and
negatively correlated (r = −.13 to–.22) with GAD7 items 1
(anxiety), 2 (uncontrollable worry), 4 (trouble relaxing),
and 5 (restlessness). All SDS items were correlated with
heroin use (r = .16 − .29), although item 5 (difficulty
abstaining) was no longer significant in the second step of
analysis after controlling for abstainers.
Alcohol use was correlated with GAD-7 item 6
(irritability; r = .14) although this relationship was not sig-
nificant after controlling for abstainers. After closer exam-
ination, we found that a v-shaped non-linear equation
offered an adequate fit to this relationship; F (4, 227) =
4.17, p < .01, weighted quadratic term p < .01. Heroin use
was negatively correlated (r = −.15) with GAD-7 item 2
(uncontrollable worry), but this was not significant at step
2. A non-linear equation did not improve model fit for this
relationship; F (4, 227) = 0.30, p = .88. Crack use was nega-
tively correlated (r = −.15 to–.17) with GAD-7 item 3 (gen-
eralised worry). Cannabis use was correlated (r = .19–
.22) with PHQ–9 item 7 (disrupted concentration). As
expected, heroin and crack use were significantly cor-
related (r = .37 − .40). After controlling for abstainers,
we observed negative correlations between alcohol
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and crack use (r = −.19), and heroin and cannabis use
(r = −.20). In these inter-substance correlations, the
more appropriate analysis was step 2, since logically
we are investigating likelihood of poly-use for those
who actively use substances. Figure 2 displays sig-
nificant non-linear associations between alcohol with
irritability (GAD-7 tem 6, r = −.19) and with difficulty
abstaining (SDS item 5, r = −.19).
Discussion
Main findings
This study presents a detailed examination of symptom-
level associations between common mental disorders
(CMD), substance use and severity of dependence. To
our knowledge, such analyses are rare [26], and offer
novel information to validate theories about comorbidity
and psychopathological processes. Consistent with the
wider literature cited above, we found significant and
moderate correlations between psychopathology and
severity of dependence in a clinical sample of drug and
alcohol users, although these were distinct and separate
dimensions. Factor analyses indicated that depression
and anxiety symptoms loaded onto a single underlying
dimension, which converges with prior studies [51, 52].
Substance use and severity of dependence were strongly
associated and mapped onto a single dimension. After
controlling for patients’ level of psychopathology repre-
sented by their CMD factor scores, we found evidence
of statistically significant albeit small correlations be-
tween substance use and psychological distress at the
Table 2 Factor structure of common mental disorder (CMD), substance use and dependence (SUD) screening tools
Sample A (N = 232) Sample B (N = 280)
Inter-factors correlation = .45 Inter-factors correlation = .43
Item Description Factor 1
(CMD)
Factor 2
(SUD)
Communality Factor 1
(CMD)
Factor 2
(SUD)
Communality
Alcohol QF Alcohol quantity x frequency of use (last week) – – .03 – – .02
Heroin QF Heroin quantity x frequency of use (last week) .53 .27 .56 .28
Crack QF Crack quantity x frequency of use (last week) .36 .11 .39 .14
Cannabis QF Cannabis quantity x frequency of use (last week) – – .03 – – .02
TOP4a Self-rated psychological wellbeing -.50 .25 -.54 .27
PHQ1 Loss of interest and pleasure .53 .33 .59 .37
PHQ2 Depressed mood .80 .63 .82 .63
PHQ3 Disrupted sleeping patterns .54 .28 .58 .31
PHQ4 Lethargy .58 .34 .57 .31
PHQ5 Disruptions in appetite .52 .32 .54 .32
PHQ6 Depressive rumination .57 .58 .61 .60
PHQ7 Disrupted concentration .61 .33 .67 .39
PHQ8 Psychomotor deficits or agitation .55 .37 .59 .40
PHQ9 Suicidal ideation .61 .45 .62 .48
GAD1 Feelings of anxiety and nervousness .79 .58 .81 .62
GAD2 Impaired control over worry .93 .74 .88 .70
GAD3 Generalised worry about different things .83 .62 .82 .62
GAD4 Trouble relaxing .84 .62 .86 .66
GAD5 Restlessness .68 .50 .69 .51
GAD6 Irritability .55 .37 .57 .40
GAD7 Fear .73 .56 .63 .46
SDS1 Impaired control over substance use .90 .76 .88 .74
SDS2 Worry about missing a dose of substance use .78 .58 .76 .55
SDS3 Worry about substance use .87 .78 .87 .79
SDS4 Wish to stop substance use .83 .62 .84 .64
SDS5 Difficulty in abstaining from substance use .61 .41 .62 .41
Notes: Factor loadings smaller than cut-off of .30 were omitted. Sample A included all cases with complete data on all items. Sample B applied multivariate
imputation of missing data items. Variance explained by the factor solution was 47.5 % in sample A and 48.2 % in Sample B
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level of individual symptoms. In what follows, we
describe these patterns of associations and offer a theor-
etical interpretation of the findings.
The most prominent association pattern was that
between severity of dependence (SDS) with depres-
sive rumination, and its negative correlation with
feelings of anxiety, uncontrollable worry, restlessness
and inability to relax. This inverse pattern may
explain the unexpected residual negative correlations
between depression and anxiety symptoms (after par-
tialling out their shared psychopathology). We note
that these residual anxiety symptoms are similar to
Fig. 1 Network plots of item-level partial correlations controlling for latent psychopathology. a Controlling for common mental disorders (CMD).
b Controlling for CMD and abstainers. Notes: Only statistically significant partial correlations shown (p <.05); Solid lines = positive correlations,
dashed lines = negative correlations; Thickness of lines = strength of correlations; Her = heroin; Crk = crack; Alc = alcohol; Can = cannabis;
TOP = Treatment Outcomes Profile item 4a (psychological distress)
Fig. 2 Non-linear associations between alcohol use, dependence and anxiety symptoms. a Difficulty in abstaining from alcohol use. b Alcohol
use and feelings of irritability
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the phenomenology of craving and withdrawal [8, 9]. Fur-
ther supporting evidence was found in the partial correla-
tions (controlling for psychopathology) between worry
about missing a dose (of substance use) and psychomotor
agitation, impaired control over substance use and inabil-
ity to relax, and the finding that heavier heroin and crack
users were less prone to worry. It is plausible that more
severely dependent respondents were compulsively using
substances in a way that mitigated such feelings of rest-
lessness and craving, but this ultimately resulted in nega-
tive bouts of rumination, which in turn exacerbated wider
aspects of depressive mood.
This deduction from our findings fits within a wider
body of research. For example, Franken et al. [53]
carried out a factor analysis of two opiate craving ques-
tionnaires in a sample of 102 addiction service users and
described a 3-factor solution covering aspects of ‘desire
and intention to use’, ‘negative reinforcement’ and ‘con-
trol’. The strongest inter-factor correlation (r = .39) indi-
cated that ‘desire to use’ substances was driven by a
need to suppress worry, tension and thoughts about life
problems (‘negative reinforcement’). Furthermore, items
from the ‘control’ factor were negatively associated with
items from the other 2 domains. Craving is also known
to be associated with biased attention to environmental
cues related to substance use [54], which may partly
explain the experience of uncontrollable worry (about
substance use). On the other hand, perseverant negative
thinking (rumination) is often associated with depression
[55–57] and has been described as a transdiagnostic fac-
tor underlying several mental disorders [58]. Rumination
has been found to predict the onset of depressive symp-
toms in non-clinical samples [59–61], and it appears to
maintain symptoms of low mood and anxiety in de-
pressed patients [62].
Moreover, we found that two of the substance use
measures (heroin and alcohol) were correlated with loss
of control over substance use. This is consistent with re-
search indicating that alcohol impairs inhibitory control
[63, 64], although this is less evident for opiates [64] and
instead may reflect a psychological aspect of lower per-
ceived control over heroin use. Cannabis use was corre-
lated with impaired concentration, which reflects the
expected psychoactive effects of this substance [65]. Al-
though robust quantitative research for cannabis-
induced neurocognitive deficits is still scarce, there is
some evidence that cannabis use impairs the ability to
learn and recall new information [66].
A particularly interesting pattern of non-linear associa-
tions were found for alcohol use (Fig. 2). Moderate
drinkers had lower mean scores for feelings of irritability
compared to non-drinkers and heavy/severe users. In
addition, light drinkers reported lower levels of perceived
difficulty in abstaining compared to non-drinkers and
moderate to severe drinkers. Non-linear associations
between alcohol and psychological distress have been
reported in numerous studies [50, 67–72]. These studies
model associations based on aggregated scores, which may
mask more specific symptom-level patterns. The ‘stress
buffer’ theory [73] seems like a plausible explanation for
our findings, suggesting that a moderate dose of alcohol
use may mitigate feelings of psychological distress [74].
Still, at higher doses, alcohol may provide less protection
from irritability once inhibitory control declines, often giv-
ing way to overt aggression particularly in men with
heightened irritability [75]. An alternative explanation may
be that the findings are confounded by other sample
characteristics [76], for instance more well-adjusted re-
spondents may cluster in the ‘moderate group’. This latter
explanation seems less probable, given that moderate
drinkers seem less resilient in their efforts to abstain from
alcohol use (as shown in Fig. 1, panel a).
Strengths and limitations
An important limitation is the relatively small sample size
by comparison to epidemiological studies in this area. Our
sample size was adequately powered to undertake factor
analysis based on Bryant and Yarnold’s criteria [77], which
would require 5 respondents per item (N = 130). Still, we
note that there are divergent views about sample size cal-
culations for factor analysis, and others suggest a minimum
of 500 participants [78]. Other considerations to note
about the generalizability of these findings concern the
outpatient setting, with a majority of respondents whose
primary reason for treatment related to opiate use.
Although nearly half of all respondents reported using
alcohol, and some at a very severe level, we noted that
alcohol use was weakly correlated with only 2 SDS items,
and did not load onto factor 2. It may be that including
more participants from alcohol detox or inpatient settings
could render different patterns of correlation. It is also pos-
sible that the method of administration of the SDS meas-
ure may have influenced the strength of correlations. SDS
was rated for the primary substance of concern, which in
some cases could have been a substance other than alcohol
(e.g., heroin), and this may have therefore impacted on the
strength of observed correlations between alcohol use and
SDS. Finally, we also note that the cross-sectional nature of
these data limit the possibility of making more certain
claims about casual relationships. Our deductions from
this sample should therefore be taken as a preliminary in-
vestigation of functional links between aspects of psycho-
pathology and addictive behaviours, awaiting further
validation in prospective studies with mediational tests.
Considerations for practice and research
The emerging literature on comorbidity suggests that
substance induced depression and anxiety symptoms are
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relatively uncommon, though they may be more conspicu-
ous in addiction treatment settings. Our findings show
that after factoring out general psychological distress,
essentially no specific covariance between substance use
patterns and psychological distress items remains. This is
strong evidence that general psychological distress is a
moderator of the relationship, but it is unclear from the
current study in which direction the causal arrow points.
From this perspective, the common practice of assum-
ing that most CMD symptoms are drug-induced is ethic-
ally questionable, especially if such practices hamper
timely diagnosis and access to mental healthcare.
Psychometrically adequate screening methods are avail-
able to detect CMD in substance users [27, 41, 79, 80],
but these methods are not consistently implemented in
routine practice. Based on our symptom-level correla-
tions, we propose that diagnostic results may perhaps be
enhanced by applying a repeated screening method after
a month of watchful wait for heavy cannabis users who
show signs of severe disruption to concentration, and
heavy drinkers who show increased signs of irritability
and hyper-arousal. Residual anxiety symptoms that may
reflect craving/withdrawal phenomena should be care-
fully distinguished from generalised anxiety disorder,
possibly by supplementing screening measures with
probing questions or interviews. The training of addic-
tion treatment professionals [81, 82] in the application
of such screening methods may be an important focus of
future dissemination studies and policies.
Conclusion
After controlling for latent levels of psychopathology, we
found little evidence of associations between symptoms of
depression/anxiety with substance use. The only signifi-
cant symptom-level associations were impaired concentra-
tion linked to cannabis use and irritability linked to
alcohol use. Severity of dependence –a psychological
construct– is prominently associated with depressive
rumination, and negatively correlated with residual
anxiety symptoms related to substance use (e.g., craving).
Overall, this analysis supports a psychological understand-
ing of comorbidity; with dependence, craving, negative
reinforcement and rumination as key variables.
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